库马林-氨基酸混合物作为有前途的抗癌剂:设计,合成,对接研究和CK2抑制
Abd-Allah S El-Etrawy1,2, Ahmad Ramadan3, Farag F Sherbiny4
1Department of Chemistry, Basic Science Center, Misr University for Science and Technology (MUST) Al-Motamayez District 6th of the October City 77 Egypt.
RSC advances
|August 7, 2024
概括
新的酸衍生物显示出强大的抗癌活性,在细胞系测试中表现优于多克索鲁比辛. 最有效的化合物还抑制CK2激酶,这表明癌症治疗的双重机制.
科学领域:
- 药用化学 医学化学
- 有机合成 有机合成
- 药理学 药理学是指药理学的学科.
背景情况:
- 库马林衍生物被认为具有多种生物活性,包括抗癌性质.
- 基修改可以提高药物的疗效和标特异性.
- 癌症仍然是导致死亡的主要原因,需要新的治疗药物.
研究的目的:
- 为了合成新的单,二,三衍生物的.
- 为了评估合成的化合物对各种人类癌症细胞系的抗癌活性.
- 研究结构-活性关系 (SAR) 和潜在的作用机制,包括酶抑制.
主要方法:
- 通过阿酸合方法合成酸衍生物.
- 使用HepG-2,PC-3和Hct-116细胞系进行体外抗癌活性评估.
- 酶抑制测定用于CK2激酶和分子对接研究.
主要成果:
- 化合物7c和5b对癌细胞系表现出显著的细胞毒性,IC50值低于多克索鲁比辛.
- 化合物5b表现出强大的CK2激酶抑制 (IC50 = 0.117μM),优于对照剂罗斯科维丁.
- 与三类似物相比,单和二衍生物显示出增强的抗癌活性,其中氨基酸功能至关重要.
结论:
- 合成的酸衍生物代表着有前途的抗癌药物.
- 化合物5b的双重活性 (细胞毒性和CK2抑制) 强调了它的治疗潜力.
- 这项研究证实了氨基酸结合和ADME有利性质对抗癌疗效的重要性.
更多相关视频
相关概念视频
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Structure-Activity Relationships and Drug Design
687
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
687
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K


